Format

Send to

Choose Destination
Pharmaceutics. 2019 Mar 19;11(3). pii: E133. doi: 10.3390/pharmaceutics11030133.

Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban.

Author information

1
College of Pharmacy, Chung-Ang University, Seoul 06974, Korea. km4355@naver.com.
2
College of Pharmacy, Chung-Ang University, Seoul 06974, Korea. amybin2@naver.com.
3
Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, ON M5S 3M2, Canada. keumhan.noh@utoronto.ca.
4
College of Pharmacy, Chung-Ang University, Seoul 06974, Korea. eykimjcb777@cau.ac.kr.
5
School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea. bsshin@skku.edu.
6
College of Pharmacy, Chung-Ang University, Seoul 06974, Korea. wkang@cau.ac.kr.

Abstract

Concomitant use of rivaroxaban with non-dihydropyridine calcium channel blockers (non-DHPs) might lead to an increase of systemic rivaroxaban exposure and anticoagulant effects in relation to the inhibition of metabolic enzymes and/or transporters by non-DHPs. This study was designed to evaluate the effects of verapamil and diltiazem on the pharmacokinetics and the prolongation of prothrombin time of rivaroxaban in rats. The data were analyzed using a pharmacokinetic/pharmacodynamics (PK/PD) modeling approach to quantify the influence of verapamil. Verapamil increased the systemic exposure of rivaroxaban by 2.8-fold (p <0.001) which was probably due to the inhibition of efflux transportation rather than metabolism. Prothrombin time was also prolonged in a proportional manner; diltiazem did not show any significant effects, however. A transit PK model in the absorption process comprehensively describes the double-peaks of rivaroxaban plasma concentrations and the corresponding change of prothrombin time with a simple linear relationship. The slope of prothrombin time vs. rivaroxaban plasma concentration in rats was retrospectively found to be insensitive by about 5.4-fold compared to than in humans. More than a 67% dose reduction in rivaroxaban is suggested in terms of both a pharmacokinetic point of view, and the sensitivity differences on the prolongation of prothrombin time when used concomitantly with verapamil.

KEYWORDS:

PK/PD modeling; drug–drug interaction; prothrombin time; rivaroxaban; verapamil

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center